Is Prior Authorization Expanding for Ophthalmology in 2026?
As of September 2026, prior authorization requirements for ophthalmology procedures are expanding on two fronts. Medicare Advantage plans including Aetna and Humana now require prior authorization for cataract surgery in states such as Georgia and Florida, and CMS launched a five-year ASC prior authorization demonstration in 10 states covering blepharoplasty and botulinum toxin injections. The American Academy of Ophthalmology is actively fighting further expansion into traditional Medicare Fee-for-Service, warning that the growing PA burden delays medically necessary care and increases administrative costs for ophthalmology practices.
Medicare Advantage is the primary driver: MA plans processed nearly 53 million prior authorization determinations in 2024, and ophthalmology is one of the specialties hit hardest, especially for cataract surgery and anti-VEGF injections.
CMS ASC demonstration adds a new layer: A five-year CMS prior authorization demonstration covering blepharoplasty and botulinum toxin in ASCs is now active in 10 states, including California, Florida, Texas, and New York.
AAO is pushing back: The AAO submitted formal comments to CMS in September 2026 urging the agency to prevent PA expansion into traditional Medicare and to increase oversight of MA plans that delay care.
What the AAO Is Fighting
In September 2026, the American Academy of Ophthalmology publicly rallied against CMS expanding prior authorization requirements into traditional Medicare Fee-for-Service. AAO Medical Director for Health Policy Dr. Michael Repka stated that “the state where a Medicare Advantage beneficiary lives should not determine whether they can receive the care they need in a timely fashion,” citing Aetna and Humana Medicare Advantage plans that now require prior authorization for cataract surgery in Georgia and Florida.
The AAO’s position is that prior authorization has already caused significant harm in Medicare Advantage, where plans use PA, step therapy, and automatic downcoding to delay and deny medically necessary eye care. Traditional Medicare has historically not required prior authorization for most ophthalmology procedures, which is why the AAO is pushing CMS to prevent that expansion rather than extend it. The AAO is supporting the Improving Seniors’ Timely Access to Care Act, which would establish electronic prior authorization, real-time decisions for routinely approved services, firm response deadlines, and public reporting on MA plan utilization management practices.
For ophthalmology practices, the immediate concern is not a hypothetical future policy. It is the current reality that Medicare Advantage enrollment continues to grow, and MA plans are imposing stricter authorization requirements on high-volume ophthalmic procedures. A practice that treated PA as a Medicare Advantage annoyance five years ago now faces a system where a significant and growing share of its surgical volume requires pre-approval before the patient can be scheduled.
Where Prior Authorization Stands Today
The prior authorization landscape for ophthalmology in 2026 is a patchwork of traditional Medicare rules, Medicare Advantage plan-specific policies, and CMS demonstration programs. Here is where things stand.
| Payer Type | PA for Cataract Surgery? | PA for Injections? | PA for ASC Procedures? |
|---|---|---|---|
| Traditional Medicare | No (as of 2026) | No (as of 2026) | Demo only: 10 states, bleph/botox |
| Medicare Advantage (varies) | Yes, plan-specific | Yes, many plans | Yes, plan-specific |
| Commercial payers | Varies by contract | Varies by contract | Varies by contract |
The critical distinction is between traditional Medicare and Medicare Advantage. Traditional Medicare does not require prior authorization for most ophthalmology procedures, with the limited exception of the CMS ASC demonstration covering blepharoplasty, botulinum toxin, rhinoplasty, panniculectomy, and vein ablation in 10 states. Medicare Advantage plans set their own authorization policies, and those policies are expanding. A patient who appears to have Medicare may actually be enrolled in an MA plan with strict PA requirements, and missing that distinction at scheduling results in a claim denial after the procedure has already been performed.
In our experience matching ophthalmology practices with billing partners, the Medicare-versus-MA verification gap is the single most expensive administrative error in ophthalmic billing. A cataract surgery performed without the required MA prior authorization is a complete write-off. The procedure was medically necessary, the surgery was successful, and the claim denies because nobody checked which Medicare product the patient carried.
How Does Prior Authorization Affect Cataract and Retina Revenue?
Prior authorization delays and denials cost ophthalmology practices revenue in three ways: surgical delays that push cases into future months and compress scheduling, full claim denials when PA was required but not obtained, and administrative labor costs for staff who manage the authorization workflow.
For cataract surgery, the impact is surgical volume. A practice scheduling 20 Medicare Advantage cataract cases per month that requires PA on each one needs a staff member or workflow dedicated to obtaining and tracking those authorizations. A single missed PA on a $1,255 ASC facility fee plus the $463 physician fee creates a $1,700 write-off that no amount of appeal will recover if the authorization was never requested.
For retina practices, the impact is injection continuity. Anti-VEGF injection claims under CPT 67028 plus the drug J-code represent $1,500 to $2,500 per encounter depending on the product and the payer. MA plans that require PA or step therapy on intravitreal injections can delay treatment by 30 days or more, which in a condition like wet AMD or DME is not just a billing problem. It is a clinical problem. Across the billing companies we vet, an 18% denial rate on anti-VEGF injection claims from a specific MA plan is not unusual when the practice lacks a dedicated PA workflow for that payer. For diagnosis-level coding that supports medical necessity on these claims, see our guide on ICD-10 code H52.03.
Prior authorization is the fastest-growing administrative cost in ophthalmology billing, and the practices losing the most revenue are the ones without a dedicated PA workflow for each MA payer. An ophthalmology billing partner who tracks plan-level PA requirements, obtains authorizations before scheduling, and appeals denials on time prevents the write-offs. Ophthalmology Billco connects eye care practices with vetted billing companies, free.
How to Protect Your Practice from PA Denials
These steps prevent the most common prior authorization failures in ophthalmology billing.
1. Verify the patient’s specific Medicare product at scheduling, not at check-in. Confirm whether the patient carries traditional Medicare or a Medicare Advantage plan, and if MA, which plan and what its PA requirements are.
2. Build a PA requirement matrix for your top 10 payers. Document which procedures require authorization, which plans use step therapy, and what documentation each plan demands. Update it quarterly.
3. Submit PA requests at least 10 business days before the scheduled procedure. Many MA plans take 5 to 7 business days to process, and a denial with appeal takes longer. Submitting the day before surgery guarantees a delay or a write-off.
4. Include medical necessity documentation with every PA request. Attach the clinical notes, diagnostic test results, and the ICD-10 diagnosis that supports the procedure. Incomplete requests are the top reason for PA delays.
5. Track PA approvals with expiration dates. An authorization that was valid for 90 days and expired before the procedure was performed results in a denial. Track every approval with its start and end date.
6. Appeal every PA denial within the payer’s filing deadline. Many PA denials are overturned on appeal when complete documentation is submitted. A practice that accepts PA denials without appeal leaves recoverable revenue on the table.
In-House PA Management vs. a Billing Partner
Providers often come to us after a quarter of escalating PA denials, looking for a billing partner who already tracks MA plan authorization requirements across every payer the practice bills. The challenge is not that PA is hard to manage. The challenge is that it is hard to manage at scale when the requirements change plan by plan, state by state, and quarter by quarter.
A solo ophthalmologist with a stable patient panel and two or three MA payers can manage PA with one trained front-desk staff member. A multi-provider practice billing 15 MA plans across cataract, retina, and glaucoma encounters cannot. The authorization requirements are different for each plan, the documentation expectations are different, the appeal deadlines are different, and the step therapy rules for anti-VEGF agents are different. That complexity is exactly what a specialized ophthalmology billing company handles: not just submitting claims, but managing the pre-claim authorization workflow that determines whether the claim will pay in the first place.
One question we hear constantly from practice managers is whether the PA burden will ease as CMS implements electronic prior authorization rules. The CMS Interoperability and Prior Authorization Final Rule requires MA plans to implement electronic PA by January 2027, which should reduce processing times from days to hours for routine approvals. But the requirement to obtain PA in the first place is not going away. Electronic PA makes the process faster. It does not eliminate the process. To learn how Ophthalmology Billco matches practices with billing partners who manage the full PA workflow, visit our about us page.
Frequently Asked Questions
As of 2026, traditional Medicare does not require prior authorization for cataract surgery. However, Medicare Advantage plans set their own PA policies, and several MA plans including Aetna and Humana now require PA for cataract surgery in certain states. Always verify the patient’s specific Medicare product.
The CMS ASC prior authorization demonstration covers California, Florida, Texas, Arizona, Ohio, Tennessee, Pennsylvania, Maryland, Georgia, and New York. It applies to blepharoplasty, botulinum toxin injections, rhinoplasty, panniculectomy, and vein ablation procedures performed in ASCs.
The claim will be denied, and in most cases the denial is not appealable because the authorization was never obtained. The practice absorbs the full cost of the procedure. For a cataract surgery, that can mean a $1,700 or more write-off between the facility fee and the physician fee.
No. The CMS Interoperability and Prior Authorization Final Rule requires MA plans to implement electronic PA by January 2027, which will speed processing times. However, it does not eliminate prior authorization requirements. Practices will still need to obtain PA where the payer requires it.
Verify the patient’s specific Medicare product at scheduling by checking eligibility through your clearinghouse or the payer’s portal. A Medicare card alone does not distinguish traditional Medicare from a Medicare Advantage plan. The eligibility check confirms the plan type and its PA requirements.
The AAO submitted formal comments to CMS in September 2026 opposing PA expansion into traditional Medicare. The AAO supports the Improving Seniors’ Timely Access to Care Act, which would require electronic PA, real-time decisions, firm response deadlines, and public reporting on MA plan authorization practices.
Next Steps
For ophthalmology diagnosis coding that supports medical necessity on PA requests, see our guide on ICD-10 code H52.03.
To learn how Ophthalmology Billco matches practices with billing partners who manage the full PA workflow, visit our about us page.
If your practice does not have a dedicated PA workflow for each Medicare Advantage payer, the write-offs are already accumulating. Get matched with an ophthalmology billing partner who prevents them.
Prior authorization is expanding across ophthalmology, and the practices that absorb the most write-offs are the ones without a payer-by-payer PA workflow. Ophthalmology Billco connects eye care practices with vetted billing companies that verify MA plan status at scheduling, obtain authorizations before surgery, and appeal denials before the deadline passes. Across all 50 states, with rates starting as low as 2.95%. Comparing quotes is 100% free for providers.
